<DOC>
	<DOCNO>NCT01113502</DOCNO>
	<brief_summary>This phase I/II open label study conduct evaluate overall safety initial effectiveness investigational drug , Eltrombopag patient 60 year age old Acute Myelogenous Leukemia ( AML ) . Eltrombopag investigational drug , mean approved U.S. Food Drug Administration ( FDA ) use type disease . Approximately 35 people enrol study University Pennsylvania</brief_summary>
	<brief_title>Eltrombopag Elderly Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description>Primary Objectives ( Phase I Portion ) : 1 ) . To determine safety tolerability eltrombopag elderly subject AML 2 ) . To determine maximally tolerated initial start dose eltrombopag elderly subject AML Primary Objectives ( Phase II portion ) : 1 ) . To good define safety tolerability eltrombopag elderly patient AML maximally tolerate start dose Page 9 18 determined Phase I portion study . 2 ) . To determine incidence peripheral platelet count improvement ( use baseline response parameter define ) subject disease relate thrombocytopenia . Secondary Objectives ( Phase I II ) : 1 ) . To preliminarily determine efficacy ( use AML response criterion define ) eltrombopag elderly subject AML . 2 ) . To perform ex-vivo analysis use subject AML sample stock eltrombopag 1 ) ass leukemic proliferative capacity 2 ) investigate potential eltrombopag induce cytoxic mechanism leukemic cell death . 3 ) . To perform pharmacodynamic assessment drug activity leukemic cell use subject sample collect various time point drug exposure . 4 ) . To preliminarily correlate pharmacodynamic finding clinical response .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>A diagnosis nonM3 AML either : ) . Relapsed standard chemotherapy transplant ; Newly diagnose patient appropriate willing candidate standard induction chemotherapy Age equal great 60 Platelet count le 75 ECOG performance status 02 Life expectancy least 4 week Must able consume oral medication Must recover toxic effect prior chemotherapy Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing . For Phase I portion : Subject must nonEast Asian ( Japanese , Chinese , Taiwanese Korean ) descent . For Phase II portion subject either East Asian nonEast Asian descent . Cytotoxic chemotherapy ( include azacitadine decitabine ) within past 28 day hydroxyurea Active participation investigational treatment study AML . Known HIV Hepatitis C ECOG performance status great 2 Uncontrolled intercurrent illness include , limited : uncontrolled ongoing infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Previous therapy romiplostim TPOR agonist</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>